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Anemia treatment and decline
of renal function
To the Editor: In the August issue of Kidney Interna-
tional Gouva et al [1] reported a significant benefit in
terms of death or aggravation of renal failure in non-
diabetic patients with chronic renal failure and anemia
randomized to the early, systematic administration of ery-
thropoietin with a target hemoglobin (Hb) concentration
of 13 g/dL, compared with deferred treatment started
when Hb reached a concentration ≤9 g/dL.
Results of this well-designed study are welcome be-
cause they demonstrate a benefit of the correction of
anemia in chronic renal failure (CRF) on hard end points
(doubling of creatinine or creatinine of >8 mg/dL or ini-
tiation of renal replacement or death). This trial raises,
however, an ethical issue because American [2] and Eu-
ropean [3] guidelines published in 1997 and 1999 recom-
mended in predialysis patients a Hb concentration of 10
and 11 g/dL, respectively, based on evidence of a better
quality of life and cardiovascular protection [2, 3]. With
a baseline creatinine clearance of 26.7 ± 9.1 mL/min and
22.3 ± 6.0 mL/min in early and deferred treatment arms,
respectively, most patients in Gouva’s study were in the
target of guidelines. Moreover, this study leaves open two
important questions: the target Hb concentration and the
glomerular filtration rate (GFR) threshold for interven-
tion. It is necessary to determine if an Hb concentration
higher than recommended (≥13 g/dL) results in a slower
progression of CRF and is well tolerated. We need also
to evaluate the effects of correcting anemia earlier in the
course of CRF, when GFR is still >25 mL/min and the
correction of anemia can be expected to be more effective
on CRF progression.
The NEPHRODIAB2 study was designed to answer
these questions in type 2 diabetic patients with GFR 25
to 60 mL/min/1.73m2 and Hb 10 to 12.9 g/dL [4]. In this
randomized trial, primary end point is the decline in GFR
in normal (11-12.9 g/dL) versus high Hb concentration
(13-14.9 g/dL) arms after two years of follow-up. The
planned sample size is 204. Inclusions started in France
in February 2004.
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Reply from the Authors
We thank Dr. Villar et al for their comments. Most ex-
pert guidelines at the time that our study was designed
would probably suggest treating anemia for hemoglobin
<10 g/dL [1] or even <11 g/dL [2]. However, as these
same guidelines had acknowledged up front, “the target
hemoglobin concentration perhaps represents the most
controversial single issue in the application of epoetin to-
day” [2]. Moreover, most of the available prior evidence
pertained to patients with more advanced renal disease
than in our study and/or patients with diabetes mellitus.
Finally, the outcomes were mostly centered on quality
of life, and it is well known that quality of life can be
subject to considerable measurement error and bias [3].
Thus, we felt it was a top priority to generate appropriate
evidence for the implementation of erythropoietin treat-
ment in patients with modest renal function impairment,
rather than perpetuate a debate with limited data. We
welcome the interesting NEPHRODIAB2 study that Dr.
Villar et al are conducting, and we look forward to see-
ing their results. We believe that similar studies may need
to be conducted also in nondiabetic patients with a sim-
ilar early level of renal dysfunction. However, studying
these patient populations, especially nondiabetic ones, is
challenging. Given the early stage of disease, very few
disease progression events are likely to occur even with
considerable follow-up, and the cost-benefit of chronic
